Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381933 | 0.84 | CNR2 (0.42) | CNR2CNR1NAMPTTMEM97SIGMAR1 | |
| SCHEMBL3989553 | 0.84 | CNR2 (0.47) | CNR2CNR1TMEM97SIGMAR1HTR3A | |
| SCHEMBL4384382 | 0.83 | CNR2 (0.43) | CNR2CNR1NAMPTTMEM97SIGMAR1 | |
| SCHEMBL3995304 | 0.82 | CNR2 (0.43) | CNR2CNR1NAMPTTMEM97SIGMAR1 | |
| SCHEMBL3995445 | 0.75 | GPR55 (0.46) | CNR2CNR1TMEM97SIGMAR1 | |
| SCHEMBL3991564 | 0.72 | CCKBR (0.39) | CNR2CNR1NAMPTTMEM97SIGMAR1 | |
| SCHEMBL4377537 | 0.71 | FEN1 (0.38) | CNR2NAMPT | |
| SCHEMBL26507782 | 0.69 | ALPI (0.44) | GPR142DPP4FAPDPP8DPP9 | |
| SCHEMBL4381942 | 0.69 | CNR2 (0.51) | CNR2CNR1TMEM97SIGMAR1HTR3A | |
| SCHEMBL4384385 | 0.68 | CNR2 (0.50) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | claimed |
| EP-2114897-A2 | BENZIMIDAZOLONE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
| EP-2114897-A2 | BENZIMIDAZOLONE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | CNR2 3/4885CNR1 2/4885NAMPT 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.